Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 07:05:06 2024-04-24 am EDT			5-day change	1st Jan Change
222.4 ^CHF	-3.20%		+1.32%	-8.79%

12:46pm	ROCHE HOLDINGS AG : UBS reaffirms its Neutral rating	ZD
12:45pm	Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	RE

ROCHE HOLDINGS AG : UBS sticks Neutral

November 24, 2021 at 06:32 am EST

Analyst Michael Leuchten from UBS research gives the stock a Neutral rating. The target price remains set at CHF 360.

Latest news about Roche Holding AG

ROCHE HOLDINGS AG : UBS reaffirms its Neutral rating	06:46am	ZD
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	06:45am	RE
Roche Eyes Potential M&A Deals Amid Pipeline Restructure	06:27am	MT
ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating	04:37am	ZD
Roche Sees Return to Growth Ahead After Forex, Post-pandemic Slump Hit First-quarter Sales	04:30am	MT
ROCHE HOLDINGS AG : Jefferies reaffirms its Neutral rating	04:15am	ZD
Roche: 2% growth in sales at constant exchange rates in Q1	03:45am	CF
ROCHE HOLDINGS AG : Buy rating from Bernstein	03:44am	ZD
European shares flat, with focus on mixed bag of earnings	03:03am	RE
Correction to Roche Article	02:14am	DJ
Roche Sales Decline on Currency Hit	01:50am	DJ
Swiss Drugmaker Roche's Q1 Sales Fall; FY24 Outlook Confirmed	01:18am	MT
Roche Q1 sales down 6% on forex effect, loss of COVID revenue	01:10am	RE
Roche Holding AG Reports Sales Results for the First Quarter Ended March 2024	01:00am	CI
Roche Holding AG Provides Earnings Guidance for the Year 2024	01:00am	CI
EMEA Morning Briefing: Shares May Rise as Investors Brace for Earnings	12:18am	DJ
Swiss Equities Flash Green; Middle East Tensions Rise	Apr. 19	MT
Roche: approval in lung cancer in the United States	Apr. 19	CF
Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	Apr. 19	MT
Roche's Lung-Cancer Drug Alecensa Gets New FDA Approval	Apr. 19	DJ
Roche's Early-stage Lung Cancer Treatment Alecensa Wins US FDA Nod	Apr. 19	MT
FDA Approves Roche?s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer	Apr. 19	CI
Roche's Genentech Gets FDA Approval for Lung-Cancer Treatment	Apr. 18	DJ
ROCHE HOLDINGS AG : UBS sticks Neutral	Apr. 18	ZD
Roche’s Multiple Sclerosis Injection Controls Relapses, Brain Lesions in Late-stage Trial	Apr. 17	MT

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

01:00am - Q1 2024 Sales and Revenue Release

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : Q4 miss weighed heavily on the healthy 2024 guidance

February 01, 2024 at 07:42 am EST

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am EST

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

229.7 CHF

Average target price

281.1 CHF

Spread / Average Target

+22.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	-8.79%	204B
ELI LILLY AND COMPANY	+27.92%	672B
NOVO NORDISK A/S	+27.22%	570B
JOHNSON & JOHNSON	-4.59%	360B
MERCK & CO., INC.	+16.38%	321B
ABBVIE INC.	+9.39%	300B
ASTRAZENECA PLC	+7.40%	217B
NOVARTIS AG	+6.21%	199B
PFIZER, INC.	-8.58%	149B
AMGEN INC.	-4.99%	147B

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : UBS sticks Neutral

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals